Table 1.
Functional nanoparticles in clinical translation.
| Formulation | Active Ingredient | Trademark | Label Indication | Status |
|---|---|---|---|---|
| Albumin NP | Paclitaxel | Abraxane | Breast, lung, and pancreatic cancer | Approved |
| Inorganic nanoparticles | Ferric oxide | Feraheme | Iron deficiency anemia (chronic kidney disease) | Approved |
| Silicon dioxide | Cornell Dots | Imaging: melanoma, brain tumor | Preclinical trial | |
| Silica dioxide-gold | AuroLase | Lung cancer (photothermal therapy) | Preclinical trial | |
| Liposomes | Doxorubicin | Doxil | Kaposi sarcoma, breast cancer, ovarian cancer, multiple myeloma | Approved |
| Daunorubicin | DaunoXome | Kaposi sarcoma | Approved | |
| Doxorubicin | Myocet | Metastatic breast cancer | Approved | |
| Paclitaxel | Lipusu | Ovarian cancer, metastatic gastric cancer | Approved | |
| Mifamurtide | MEPACT | Osteosarcoma | Approved | |
| Vincristine sulfate | Marqibo | Acute lymphoblastic leukemia | Approved | |
| Irinotecan | Onivyde | Metastatic pancreatic cancer | Approved | |
| Cytarabine/daunorubicin (5:1) | VYXEOS | Acute myeloid leukemia | Approved | |
| Cisplatin | Lipolatin | Non-small cell lung cancer | Clinical trial phase 3 | |
| Irinotecan | IHL-305 | Advanced stage of solid tumor | Clinical trial phase 1 | |
| Nanoparticles | Paclitaxel | DHP107 | Advanced gastric cancer | Approved |
| Doxorubicin | Transdrug® | Hepatocellular carcinoma | Approved | |
| Docetaxel | BIND-014 | Advanced non-small cell lung cancer | Clinical trial phase 2 | |
| Camptothecin | CRLX101 | Advanced non-small cell lung cancer | Clinical trial phase 2 | |
| Anti-RRM2 siRNA | CALAA-01 | Solid tumor | Clinical trial phase 1 | |
| Paclitaxel | Nanoxel® | Advanced stage of breast cancer | Clinical trial phase 1 | |
| Paclitaxel | PICN | Metastatic breast cancer | Approved | |
| Polymer-drug conjugate | Asparaginase | Oncaspar® | Leukemia | Clinical trial phase 3 |
| Paclitaxel | Xyotax® | Breast cancer, ovarian cancer | Clinical trial phase 3 | |
| Paclitaxel | Taxoprexin® | Solid tumor | Clinical trial phase 2 | |
| Camptothecin | XMT-1001 | Non-small cell lung cancer | Clinical trial phase 1 | |
| Paclitaxel | Genexol-PM | Breast cancer, lung cancer | Approved | |
| Polymeric micelles | Paclitaxel | Nanoxel | Breast cancer, ovarian cancer | Approved |
| Paclitaxel | Paclical | Ovarian cancer | Approved | |
| Doxorubicin | Themodox® | Breast, lung cancer | Clinical trial phase 3 | |
| Paclitaxel | Genexol®-PM | Breast cancer, lung cancer, pancreatic cancer | Approved | |
| Paclitaxel | Paclical® | Ovarian cancer | Approved | |
| Paclitaxel | NK105 | Gastric cancer | Clinical trial phase 3 | |
| Oxaliplatin | NC-4016 | Solid tumor | Clinical trial phase 1 | |
| Cisplatin | NC-6004 | Pancreatic cancer | Clinical trial phase 3 | |
| 7-ethyl-10-hydroxycamptothecin | NK012 | Triple-negative breast cancer | Clinical trial phase 2 |